liraglutide (rD N A origin) injection
Im portant Patient Inform ation
This is a BRIEF SUM M ARY of im portant inform ation about
Victoza®. This inform ation does not take the place of
talking w ith your doctor about your medical condition or
your treatm ent. If you have any questions about Victoza®,
ask your doctor. Only your doctor can determ ine if
Victoza® is right fo r you.
WARNING
During the drug testing process, the medicine in Victoza®
caused rats and mice to develop tum ors of the thyroid
gland. Some of these tum ors w ere cancers. It is not
know n if Victoza® w ill cause thyroid tum ors or a type of
thyroid cancer called m edullary thyroid cancer (MTC) in
people. If MTC occurs, it m ay lead to death if not detected
and treated early. Do not take Victoza® if you or any of
your fam ily members have MTC, or if you have M ultiple
Endocrine Neoplasia syndrome type 2 (MEN 2). This is
a disease w here people have tum ors in more than one
gland in the body.
W hat is Victoza® used for?
Victoza® is a glucagon-like-peptide-1
(GLP-1) receptor
agonist used to improve blood sugar (glucose) control in
adults with type 2 diabetes mellitus, when used with a diet
and exercise program.
Victoza® should not be used as the first choice of medicine
for treating diabetes.
Victoza® has not been studied in enough people with a
history of pancreatitis (inflammation of the pancreas).
Therefore, it should be used with care in these patients.
Victoza® is not for use in people with type 1
diabetes
mellitus or people with diabetic ketoacidosis.
It is not known if Victoza® is safe and effective when used
with insulin.
W ho should not use Victoza®?
Victoza® should not be used in people with a personal or
family history of MTC or in patients with MEN 2.
W hat is the most im portant inform ation I should know
about Victoza®?
In animal studies, Victoza® caused thyroid tumors. The
effects in humans are unknown. People who use Victoza®
should be counseled on the risk of MTC and symptoms of
thyroid cancer.
In clinical trials, there were more cases of pancreatitis in
people treated with Victoza® compared to people treated
with other diabetes drugs. If pancreatitis is suspected,
Victoza® and other potentially suspect drugs should
be discontinued. Victoza® should not be restarted if
pancreatitis is confirmed. Victoza® should be used with
caution in people with a history of pancreatitis.
Serious low blood sugar (hypoglycemia) may occur when
Victoza® is used with other diabetes medications called
sulfonylureas. This risk can be reduced by lowering the
dose of the sulfonylurea.
Like all other diabetes medications, Victoza® has not been
shown to decrease the risk of large blood vessel disease
(i.e. heart attacks and strokes).
W h at are the side effects of Victoza®?
Tell your healthcare provider if you get a lump or swelling
in your neck, hoarseness, trouble swallowing, or shortness
of breath while taking Victoza®. These may be symptoms
of thyroid cancer.
The most common side effects, reported in at least 5 %
of people treated with Victoza® and occurring more
commonly than people treated with a placebo (a non-
active injection used to study drugs in clinical trials) are
headache, nausea, diarrhea, and resistance to liraglutide
(antibody formation).
Immune system related reactions, including hives, were
more common in people treated with Victoza® (0.8%)
compared to people treated with other diabetes drugs
(0.4%) in clinical trials.
This listing of side effects is not complete. Your health care
professional can discuss with you a more complete list of
side effects that may occur when using Victoza®.
W h at should I know about taking Victoza® w ith other
medications?
Victoza® slows emptying of your stomach. This may impact
how your body absorbs other drugs that are taken by
mouth at the same time.
Can Victoza® be used in children?
Victoza® has not been studied in people below 18 years of
age.
Can Victoza® be used in people w ith kidney or liver
problems?
There is limited data on using Victoza® in people with
kidney or liver problems. Victoza® should be used with
caution in these types of people.
Still have questions?
This is only a summary of important information. Ask your
doctor for more complete product information, or
call 1-877-4VICTOZA (1-877-484-2869)
visit victoza.com
V i c t o z a
®
i s a r e g i s t e r e d t r a d e m a r k o f
N o v o N o r d i s k A / S .
Date of Issue: Jan 2010
Version 1
© 2010 Novo Nordisk A/S.
141826
June 2010
novo nordisk
previous page 141 Better Homes And Gardens 2011 03 read online next page 143 Better Homes And Gardens 2011 03 read online Home Toggle text on/off